Format

Send to

Choose Destination
Stem Cell Res Ther. 2011 Dec 7;2(6):47. doi: 10.1186/scrt88.

Eyes open to stem cells: safety trial may pave the way for cell therapy to treat retinal disease in patients.

Abstract

A clinical trial using human embryonic stem cell (hESC) therapy for an inherited retinal degenerative disease is about to commence. The Advanced Cell Technology (ACT) trial will treat patients with Stargardt's macular dystrophy using transplanted retinal pigment epithelium derived from hESCs. Currently, no effective treatment is available for Stargardt's disease so a stem cell-based therapy that can slow progression of this blinding condition could represent a significant breakthrough. While there are some hurdles to clear, the ACT trial is a fine example of translational research that could eventually pave the way for a range of stem cell therapies for the retina and other tissues.

PMID:
22152341
PMCID:
PMC3340556
DOI:
10.1186/scrt88
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center